Get the Stockscreener App
45.25
2.17%
0.96
After Hours:
45.50
0.25
+0.55%
Veracyte Inc stock is traded at $45.25, with a volume of 1.33M.
It is up +2.17% in the last 24 hours and down -18.63% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$44.29
Open:
$44.2
24h Volume:
1.33M
Relative Volume:
1.01
Market Cap:
$3.64B
Revenue:
$541.74M
Net Income/Loss:
$88.01M
P/E Ratio:
41.66
EPS:
1.0862
Net Cash Flow:
$155.34M
1W Performance:
+8.28%
1M Performance:
-18.63%
6M Performance:
+23.67%
1Y Performance:
+58.16%
1-Day Range:
$44.19
$45.50
1-Week Range:
$41.02
$45.50
52-Week Range:
$28.55
$60.91
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
45.25 | 3.36B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Virtus Advisers LLC Purchases New Shares in Veracyte, Inc. $VCYT - MarketBeat
Great Lakes Advisors LLC Invests $3.85 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (VCYT): Moves 0.50% Down to $41.98 on the Day; Trading Range: the Price Remains Bounded by the Supplied Support and ResistanceDividend Arbitrage - vinanet.vn
Lisanti Capital Growth LLC Purchases Shares of 63,400 Veracyte, Inc. $VCYT - MarketBeat
Top 3 Health Care Stocks That Could Blast Off This Month - Benzinga
Summit Creek Advisors LLC Takes Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (VCYT) Results at a Glance: EPS Clears the Reported Estimate in Latest Trading; Stock Move: Shares Move Lower 2.50%Investor Earnings Call - vinanet.vn
Rice Hall James & Associates LLC Invests $5.61 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte Inc (VCYT) News, Articles, Events & Latest Updates - Stocktwits
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround - Yahoo Finance
Is Veracyte (VCYT) Undervalued As Raised 2026 Outlook And Q2 Earnings Lift Interest? - Sahm
Veracyte Inc (VCYT) Shares Fall 3.2% -- GF Value Says Still Over - GuruFocus
Veracyte Debuts Prosigna Breast Test in the U.S. - Medical Product Outsourcing
Zacks Research Upgrades Veracyte (NASDAQ:VCYT) to Strong-Buy - MarketBeat
Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
A Look at Veracyte Inc (VCYT) After 3.7% Decline -- GF Value $38 - GuruFocus
Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT - MarketBeat
How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit - Sahm
Veracyte at canaccord growth conference: growth balanced with margins By Investing.com - Investing.com Canada
Veracyte at canaccord growth conference: growth balanced with margins - Investing.com
Veracyte (VCYT) Dropped, So What Is Behind The Latest Attention? - Sahm
Veracyte: Diagnostics With Favorable Economics (NASDAQ:VCYT) - Seeking Alpha
Veracyte: Core Growth Funds Prosigna And TrueMRD (NASDAQ:VCYT) - Seeking Alpha
Royal Bank of Canada Grows Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat
Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC - MarketBeat
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Cuts Target Price to $50 - Moomoo
Empowered Funds LLC Buys 68,171 Shares of Veracyte, Inc. $VCYT - MarketBeat
Results: Veracyte, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential - ChartMill
Renaissance Technologies LLC Takes Position in Veracyte, Inc. $VCYT - MarketBeat
VERACYTE INC : PIPER SANDLER CUTS TARGET PRICE TO $54.00 FROM $66.00 - Bitget
Medicare Coverage Granted for Veracyte’s Test for Muscle-Invasive Bladder Cancer - Medical Product Outsourcing
Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT) - The Globe and Mail
Stephens Issues Pessimistic Forecast for Veracyte (NASDAQ:VCYT) Stock Price - MarketBeat
Veracyte (NASDAQ:VCYT) Price Target Cut to $44.00 by Analysts at Morgan Stanley - MarketBeat
Veracyte, Inc. (VCYT): Investor Outlook Reveals a 31.35% Potential Upside Amid Strong Analyst Ratings - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Takes Position in Veracyte, Inc. $VCYT - marketbeat.com
Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests - webull.com
Canaccord cuts Veracyte stock price target to $50 on revenue outlook - Investing.com Nigeria
VERACYTE INC : CANACCORD GENUITY CUTS TARGET PRICE TO $50 FROM $60 - Bitget
Veracyte (VCYT) Plunges 22.5%: Critical Support Level in Focus After Steep SelloffDouble Top - Vinanet
VERACYTE, INC. 2026: Revenue $150.32M, EPS $0.31— 10-Q Summary - TradingView
Veracyte | 10-Q: Q2 2026 Earnings Report - Moomoo
Piper Sandler Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $66 - moomoo.com
Needham raises Veracyte stock price target to $69 on strong Q2 beat - Investing.com Nigeria
Veracyte (NASDAQ:VCYT) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Transcript : Veracyte, Inc., Q2 2026 Earnings Call, Jul 30, 2026 - marketscreener.com
Is Veracyte Inc (VCYT) Still a Strong Investment After Q2 Earnin - GuruFocus
Earnings call transcript: Veracyte beats Q2 2026 estimates but shares fall after hours - Investing.com
Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised - Moomoo
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):